Valneva Announces Successful Outcome of its Annual General Meeting

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors

Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company’s Annual General Meeting (AGM), held earlier today in Lyon, France.

Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company’s share capital, and the transfer of Valneva’s registered office to Lyon following the closure of its Nantes site.

Shareholders also approved the reappointment of five Board members. Anne-Marie Graffin, James Sulat and Kathrin Jansen were reappointed for one-year terms, James Connelly for a two-year term, and Valneva’s Chief Executive Officer Thomas Lingelbach for a three-year term.

At a Board meeting held following the AGM, Dr. Gerd Zettlmeissl, an independent director, was appointed as Chair of the Board of Directors. Dr. Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 40 years of scientific and leadership experience in the biopharmaceutical industry. During the last 15 years he served as chair of the Board of Directors of several non-profit vaccine organizations as well as public and private biotech companies. He succeeds Anne-Marie Graffin, who chaired the Board for the past three years and who will continue as Vice-chair of the Board.

Gerd Zettlmeissl, chair of Valneva´s Board of Directors, commented, “I am honored to be appointed chair of the Board and would like to thank Anne-Marie for her outstanding leadership during her tenure. I look forward to working closely with my fellow board colleagues and the management team to support Valneva’s strategic priorities and long-term value creation for shareholders.”

Detailed voting results will be made available in the “Investors & Media” section of Valneva’s corporate website in the coming days.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Media and Investor Relations Contacts Laetitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 [email protected]

Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 [email protected]